Can Systems Biology Advance Clinical Precision Oncology?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Dec 24

PMID 34944932

Citations 7

Authors

Andrea Rocca

Boris N Kholodenko

Affiliations

Soon will be listed here.

Abstract

Precision oncology is perceived as a way forward to treat individual cancer patients. However, knowing particular cancer mutations is not enough for optimal therapeutic treatment, because cancer genotype-phenotype relationships are nonlinear and dynamic. Systems biology studies the biological processes at the systems' level, using an array of techniques, ranging from statistical methods to network reconstruction and analysis, to mathematical modeling. Its goal is to reconstruct the complex and often counterintuitive dynamic behavior of biological systems and quantitatively predict their responses to environmental perturbations. In this paper, we review the impact of systems biology on precision oncology. We show examples of how the analysis of signal transduction networks allows to dissect resistance to targeted therapies and inform the choice of combinations of targeted drugs based on tumor molecular alterations. Patient-specific biomarkers based on dynamical models of signaling networks can have a greater prognostic value than conventional biomarkers. These examples support systems biology models as valuable tools to advance clinical and translational oncological research.

Citing Articles

Digital Cancer Care and the Vision for Transforming the Quality of Care.

Nelson H, Chan K, Palis B J Registry Manag. 2025; 51(3):104-108.

PMID: 39897604 PMC: 11781280.

Pharmacological approaches to understanding protein kinase signaling networks.

Stephenson E, Higgins J Front Pharmacol. 2024; 14:1310135.

PMID: 38164473 PMC: 10757940. DOI: 10.3389/fphar.2023.1310135.

Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis.

Khilwani R, Singh S Biomedicines. 2023; 11(10).

PMID: 37893079 PMC: 10604646. DOI: 10.3390/biomedicines11102706.

Treatment of evolving cancers will require dynamic decision support.

Strobl M, Gallaher J, Robertson-Tessi M, West J, Anderson A Ann Oncol. 2023; 34(10):867-884.

PMID: 37777307 PMC: 10688269. DOI: 10.1016/j.annonc.2023.08.008.

Clinical Network Systems Biology: Traversing the Cancer Multiverse.

Mambetsariev I, Fricke J, Gruber S, Tan T, Babikian R, Kim P J Clin Med. 2023; 12(13).

PMID: 37445570 PMC: 10342467. DOI: 10.3390/jcm12134535.

References

Brackston R, Lakatos E, Stumpf M . Transition state characteristics during cell differentiation. PLoS Comput Biol. 2018; 14(9):e1006405. PMC: 6168170. DOI: 10.1371/journal.pcbi.1006405. View

Molinelli E, Korkut A, Wang W, Miller M, Gauthier N, Jing X . Perturbation biology: inferring signaling networks in cellular systems. PLoS Comput Biol. 2013; 9(12):e1003290. PMC: 3868523. DOI: 10.1371/journal.pcbi.1003290. View

Villaverde A, Banga J . Reverse engineering and identification in systems biology: strategies, perspectives and challenges. J R Soc Interface. 2013; 11(91):20130505. PMC: 3869153. DOI: 10.1098/rsif.2013.0505. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Ciardiello F, Arnold D, Casali P, Cervantes A, Douillard J, Eggermont A . Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014; 25(9):1673-1678. DOI: 10.1093/annonc/mdu217. View

Haury A, Mordelet F, Vera-Licona P, Vert J . TIGRESS: Trustful Inference of Gene REgulation using Stability Selection. BMC Syst Biol. 2012; 6:145. PMC: 3598250. DOI: 10.1186/1752-0509-6-145. View

Das S, McClain C, Rai S . Fifteen Years of Gene Set Analysis for High-Throughput Genomic Data: A Review of Statistical Approaches and Future Challenges. Entropy (Basel). 2020; 22(4). PMC: 7516904. DOI: 10.3390/e22040427. View

Sneddon M, Faeder J, Emonet T . Efficient modeling, simulation and coarse-graining of biological complexity with NFsim. Nat Methods. 2010; 8(2):177-83. DOI: 10.1038/nmeth.1546. View

Xiong W, Ferrell Jr J . A positive-feedback-based bistable 'memory module' that governs a cell fate decision. Nature. 2003; 426(6965):460-5. DOI: 10.1038/nature02089. View

10.

Heasman S, Ridley A . Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008; 9(9):690-701. DOI: 10.1038/nrm2476. View

11.

Kalemkerian G, Narula N, Kennedy E, Biermann W, Donington J, Leighl N . Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association.... J Clin Oncol. 2018; 36(9):911-919. DOI: 10.1200/JCO.2017.76.7293. View

12.

Sjostrom M, Chang S, Fishbane N, Davicioni E, Zhao S, Hartman L . Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. J Clin Oncol. 2019; 37(35):3340-3349. PMC: 6901281. DOI: 10.1200/JCO.19.00761. View

13.

Arpino G, Wiechmann L, Osborne C, Schiff R . Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29(2):217-33. PMC: 2528847. DOI: 10.1210/er.2006-0045. View

14.

Eduati F, Doldan-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F . Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. Cancer Res. 2017; 77(12):3364-3375. PMC: 6433282. DOI: 10.1158/0008-5472.CAN-17-0078. View

15.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

16.

Mekedem M, Ravel P, Colinge J . Application of modular response analysis to medium- to large-size biological systems. PLoS Comput Biol. 2022; 18(4):e1009312. PMC: 9060349. DOI: 10.1371/journal.pcbi.1009312. View

17.

Kolch W, Pitt A . Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 2010; 10(9):618-29. DOI: 10.1038/nrc2900. View

18.

Gillespie D . Stochastic simulation of chemical kinetics. Annu Rev Phys Chem. 2006; 58:35-55. DOI: 10.1146/annurev.physchem.58.032806.104637. View

19.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Aktan G . Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012; 30(21):2585-92. DOI: 10.1200/JCO.2011.35.6725. View

20.

Kholodenko B . Spatially distributed cell signalling. FEBS Lett. 2009; 583(24):4006-12. PMC: 2795127. DOI: 10.1016/j.febslet.2009.09.045. View